BioOra and Cincinnati Children's Hospital Collaborate on CAR-T Therapy for Pediatric Leukemia
BioOra Limited and Cincinnati Children's Hospital Medical Center have announced a partnership to advance Atla-cel, a third-generation CAR-T cell therapy, for children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). This therapy, which has shown reduced neurotoxicity in adult trials, aims to provide a safer and more effective treatment option for pediatric patients. Cincinnati Children's will lead a global clinical program to evaluate Atla-cel, leveraging its expertise in pediatric oncology and cellular therapies. The collaboration seeks to address the limitations of current CAR-T therapies, particularly the neurotoxicity risks that are significant in children. 
